Abstract:Abstract This abstract discusses an unusual rash caused by an atypical infection in a susceptible individual. A 52-year-old patient was referred in 2022 with a 12-month history of a progressive rash on the right leg with tender, inflamed and erythematous lesions. The patient had a background of severe relapsing polychondritis that was diagnosed in 2016. The disease was being managed with prednisolone 30 mg once daily, after previous failure of other immunosuppressive agents including methotrexate, azathioprine and 6 cycles of IV cyclophosphamide. Additionally, the patient was also on co-trimoxazole for Pneumocystis jirovecii pneumonia prophylaxis. On examination, erythematous and violaceous plaques and nodules were noted at the right leg with the lesions clustering and coalescing at the right medial thigh. A few of the lesions appeared infiltrated with pale material. Several warts were noted on the dorsal aspect of the hands, indicating significant immunosuppression. Differential diagnoses considered included the following: a vasculitic process, deposition disorders or an infective process. An urgent biopsy revealed palisaded granulomatous and neutrophilic dermatosis, indicative of an infectious aetiology. The patient was referred to the infectious diseases team. Acid alcohol-fast bacteria culture and whole-genome sequencing revealed a diagnosis of Mycobacteroides chelonae, a nontuberculous mycobacterium. The patient was commenced on 6 months’ treatment with combined doxycycline 100 mg twice daily and clarithromycin 500 mg twice daily. The patient responded well to treatment, with resolution of nodules on treatment completion. This case highlights the need for an increased index of suspicion in patients with a history of significant immunosuppression. Our patient had undergone QuantiFERON Gold (negative) in 2020 prior to IV cyclophosphamide. There is some evidence to suggest that QuantiFERON Gold may have the capacity to identify patients with nontuberculous mycobacteria (Kobashi Y, Mouri K, Yagi S et al. Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis 2009; 13: 1422–6). There is robust guidance on TB infection screening prior to initiating immunosuppression (interferon-γ release assay and chest radiograph) [National Institute for Health and Care Excellence. Scenario: monitoring of DMARDs. Available at https://cks.nice.org.uk/topics/dmards/management/monitoring-of-dmards/ (last accessed 24 March 2024)]. However, there is a relative paucity of guidance related to infection monitoring after commencement of immunosuppression and the need for repeat QuantiFERON testing. Given the increasing use of complex chemotherapy and immunosuppression regimens in standard practice, retaining a high index of suspicion for complex or atypical infection remains important and serves to highlight the need for appropriate investigation. Developing appropriate guidelines to rationalize infection monitoring of patients on long-term immunosuppression could further improve patient care.

Prevalence and clinical manifestations of cutaneous findings in patients with adult‐onset immunodeficiency due to anti‐interferon gamma autoantibodies: an eight‐year retrospective study

Drug-induced Erythroderma in Patients with Acquired Immunodeficiency Syndrome.

Underlying Systemic Diseases in Interstitial Granulomatous Dermatitis and Palisaded Neutrophilic Granulomatous Dermatitis: A Systematic Review

Gut microbiome profiles and associated metabolic pathways in patients of adult-onset immunodeficiency with anti-interferon-gamma autoantibodies

BI35 A 12-month history of a progressive rash on a background of significant long-term immunosuppression

Distinct Lymphocyte Immunophenotyping and Quantitative Anti-Interferon Gamma Autoantibodies in Taiwanese HIV-Negative Patients with Non-Tuberculous Mycobacterial Infections

Juvenile-Onset Immunodeficiency Secondary to Anti-Interferon-Gamma Autoantibodies

Clinical Immunological Characteristics of Anti-Interferon-γ Autoantibodies Syndrome: A 3 Year Prospective Cohort Study

Pathogen spectrum and immunotherapy in patients with anti-IFN-γ autoantibodies: A multicenter retrospective study and systematic review

Characteristics and Outcomes of Anti-interferon Gamma Antibody-Associated Adult Onset Immunodeficiency

Mycobacterium abscessus subspecies massiliense infection with anti-interferon-gamma autoantibodies

P102 Cutaneous noninfectious manifestations of chronic granulomatous disease: a prospective study

Longitudinal Analysis Over Decades Reveals the Development and Immune Implications of Type I Interferon Autoantibodies in an Aging Population

The unique diagnostic and management challenge of a patient with concomitant anti-interferon-gamma autoantibody associated immunodeficiency syndrome, IgG4-related disease, and treatment refractory, disseminated mycobacterium avium complex infection

The intersection of dermatology and immunology: Cutaneous manifestations, autoantibodies and quality of life in connective tissue diseases

Dermatology facing autoinflammatory syndrome

P1002 De novo and drug-induced skin manifestations in Inflammatory Bowel Disease patients: The impact of anti-tumour necrosis factor therapy

Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-γ immunodeficiency: a prospective cohort study

Disseminated Mycolicibacter arupensis and Mycobacterium avium co-infection in a patient with anti-interferon-γ neutralizing autoantibody-associated immunodeficiency syndrome

Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases

Development of intravascular large B-cell lymphoma during prophylactic antibiotic treatment for anti-interferon-gamma autoantibody syndrome: A case report